A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Adicet Bio, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 1,512,600 shares of ACET stock, worth $2.25 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,512,600
Previous 1,049,000 44.19%
Holding current value
$2.25 Million
Previous $2.47 Million 25.76%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$1.21 - $2.4 $560,956 - $1.11 Million
463,600 Added 44.19%
1,512,600 $1.83 Million
Q1 2024

May 13, 2024

BUY
$1.76 - $3.45 $497,024 - $974,280
282,400 Added 36.84%
1,049,000 $2.47 Million
Q4 2023

Feb 13, 2024

BUY
$1.11 - $1.89 $99,456 - $169,344
89,600 Added 13.23%
766,600 $1.45 Million
Q3 2023

Nov 14, 2023

BUY
$1.37 - $3.4 $639,237 - $1.59 Million
466,597 Added 221.76%
677,000 $927,000
Q2 2023

Aug 11, 2023

SELL
$2.13 - $7.13 $224,495 - $751,480
-105,397 Reduced 33.37%
210,403 $511,000
Q1 2023

May 12, 2023

BUY
$5.52 - $9.23 $1.58 Million - $2.64 Million
286,100 Added 963.3%
315,800 $1.82 Million
Q4 2022

Feb 13, 2023

BUY
$7.72 - $21.27 $229,284 - $631,719
29,700 New
29,700 $266,000
Q2 2022

Aug 12, 2022

BUY
$10.26 - $20.81 $1.29 Million - $2.61 Million
125,500 New
125,500 $1.83 Million
Q4 2021

Feb 11, 2022

SELL
$7.37 - $17.49 $311,139 - $738,375
-42,217 Closed
0 $0
Q3 2021

Nov 12, 2021

SELL
$6.29 - $9.93 $248,348 - $392,066
-39,483 Reduced 48.33%
42,217 $331,000
Q2 2021

Aug 13, 2021

BUY
$9.19 - $15.93 $566,104 - $981,288
61,600 Added 306.47%
81,700 $841,000
Q1 2021

May 13, 2021

BUY
$12.12 - $17.17 $243,611 - $345,117
20,100 New
20,100 $263,000

Others Institutions Holding ACET

About Adicet Bio, Inc.


  • Ticker ACET
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,030,800
  • Market Cap $59.6M
  • Description
  • Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...
More about ACET
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.